LACRIMAL IMPLANT BODY INCLUDING COMFORTING AGENT

• US 20100274224A1
• Filed: 07/08/2009
• Published: 10/28/2010
• Est. Priority Date: 07/08/2008
• Status: Abandoned Application

• Current Assignee: Mati Therapeutics, Inc
• Original Assignee: QLT Plug Delivery, Inc.
• Inventors: Sim, Sylvie, Shimizu, Robert W., Jain, Rachna, Rapacki, Alan R.
• Application Number:
  US12/499,605
• Publication Number:
  US 20100274224A1
• Time in Patent Office: Days
• US Class Current: 604/514
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00772 Apparatus for restoration of tear ducts

Abstract

Lacrimal implants for treating ocular diseases are disclosed. More particularly, lacrimal punctal plugs, methods of making such plugs, and methods of treating ocular diseases using such plugs are disclosed.

Claims

1. (canceled)

2. A punctum plug insertable into a lacrimal punctum for release of one or more comforting agents to an eye, the punctum plug comprising:

a plug body having a proximal end portion adapted to be disposed near the punctal opening and a distal end portion adapted to be disposed within the punctal canal;

wherein the punctum plug provides release of the one or more comforting agents to the eye.

3. The punctum plug of claim 2, wherein at least one of the one or more comforting agents is a demulcent or emollient.

5. The punctum plug of claim 2, wherein the one or more comforting agents is embedded in the plug body or coated on the surface of the plug body.

7. The punctum plug of claim 2, wherein the one or more comforting agents is infused or mixed into the plug body.

9. The punctum plug of claim 2, further comprising an agent core inserted at or near the proximal end portion.

10. The punctum plug of claim 9, wherein the agent core provides release of a therapeutic agent or agents, the one or more comforting agents, or both, to the eye.

11. The punctum plug of claim 9, wherein both the agent core and the plug body provide release of the one or more comforting agents to the eye.

13. The punctum plug of claim 2, wherein the one or more comforting agents is selected from the group consisting of polyvinyl alcohol (PVA), polyethylene oxide (PEO), polyvinyl pyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), carboxy methylcellulose (CMC), glycerin, simethicone, and sodium hyaluronate.

14. The punctum plug of claim 2, wherein the punctum plug further provides release of a therapeutic agent or agents to the eye.

17. The punctum plug of claim 2, wherein the plug body comprises a silicone, a silicone copolymer, a polyurethane, a polyurethane copolymer, a polyurethane-silicone copolymer, or any combination thereof.

4. (canceled)

6. (canceled)

8. (canceled)

12. (canceled)

15-16. -16. (canceled)

18-20. -20. (canceled)

21. A punctum plug insertable into a lacrimal punctum for release of a therapeutic agent or agents, a comforting agent or agents, or both to an eye, the punctum plug comprising:

a plug body having a proximal end portion adapted to be disposed near the punctal opening and a distal end portion adapted to be disposed within the punctal canal;

an agent core at or near the proximal end portion;

a retention structure at or near the distal end portion; and

wherein the agent core or the plug body has at least one surface that provides release of the therapeutic agent or agents, the comforting agent or agents, or both, to the eye.

22. The plug of claim 21, wherein the agent core or the plug body provides release of the therapeutic agent or agents.

24. The plug of claim 21, wherein both the agent core and the plug body provide release of the therapeutic agent or agents.

25. The plug of claim 21, wherein the agent core or the plug body provides release of the comforting agent or agents.

27. The plug of claim 21, wherein both the agent core and the plug body provide release of the comforting agent or agents.

28. The plug of claim 21, wherein the agent core or the plug body provides release of both the therapeutic agent or agents and the comforting agent or agents.

29. The plug of claim 21, wherein the agent core and the plug body provide release of both the therapeutic agent or agents and the comforting agent or agents.

30. The punctum plug of claim 21, wherein the comforting agent is a demulcent or emollient.

31. The punctum plug of claim 21, wherein the release of the therapeutic agent or agents is a sustained release.

33. The punctum plug of claim 21, wherein the plug body comprises a silicone, a silicone copolymer, a polyurethane, a polyurethane copolymer, a polyurethane-silicone copolymer, or any combination thereof.

35. The punctum plug of claim 21, wherein the comforting agent is selected from the group consisting of polyvinyl alcohol (PVA), polyethylene oxide (PEO), polyvinyl pyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), carboxy methylcellulose (CMC), glycerin, simethicone, and sodium hyaluronate.

36. The punctum plug of claim 21, wherein the comforting agent or agents are coated on the surface of the plug body, agent core, or both.

37. The punctum plug of claim 21, wherein the comforting agent or agents are infused or mixed into the plug body, agent core, or both.

43. The punctum plug of claim 21, wherein the agent core comprises at least one therapeutic agent inclusion distributed in a solid matrix and at least partially covered by a sheath body to define at least one exposed agent core surface.

44. The punctum plug of claim 43, wherein the solid matrix comprises a mixture of silicone and the therapeutic agent.

45. The punctum plug of claim 43, wherein the solid matrix comprises a mixture of silicone, the therapeutic agent, and the comforting agent.

23. (canceled)

26. (canceled)

32. (canceled)

34. (canceled)

38-42. -42. (canceled)

46-53. -53. (canceled)

54. A method of manufacturing a punctum plug insertable into a lacrimal punctum for release of one or more comforting agents to an eye, the method comprising:

forming a plug body having a proximal end portion adapted to be disposed near the punctal opening and a distal end portion adapted to be disposed within the punctal canal;

wherein the punctum plug provides release of the one or more comforting agents to the eye.

55. The method of claim 54, wherein the comforting agent is a demulcent or emollient.

56. The method of claim 54, wherein forming the plug body includes:

mixing the comforting agent into a silicone;

placing the mixture into a mold; and

heat curing the mixture.

57. (canceled)

58. A method to treat a subject having an eye disorder, comprising:

inserting a punctum plug into at least one lacrimal punctum of the subject, the punctum plug comprising,

a plug body having a proximal end portion adapted to be disposed near the punctal opening and a distal end portion adapted to be disposed within the punctal canal;

wherein the plug body comprises an agent core at or near the proximal end portion and a retention structure at or near the distal end portion;

wherein the agent core comprises a therapeutic agent or agents and has at least one surface providing release of the therapeutic agent or agents to the eye; and

wherein the agent core, plug body or both provide release of a comforting agent or agents to the eye.

59. The method of claim 58, wherein the comforting agent is a demulcent or emollient.

60. The method of claim 58, wherein the comforting agent or agents are embedded in the agent core.

61. The method of claim 58, wherein the comforting agent or agents are embedded in both the agent core and plug body.

62. The method of claim 58, wherein the comforting agent or agents are coated on the surface of the plug body, agent core, or both.

63. The method of claim 58, wherein the comforting agent or agents are infused or mixed into the plug body, agent core, or both.

68. The method of claim 58, wherein the subject feels less discomfort compared to a subject who is treated with a punctum plug lacking the comforting agent or agents.

72. The method of claim 58, wherein the eye disorder is glaucoma or dry eye.

74. The method of claim 72, further comprising administering an anti-glaucoma medication selected from the group consisting of adrenergic agonists, adrenergic antagonists, carbonic anhydrase inhibitors, parasympathomimetics, prostaglandins and hypotensive lipids, and combinations thereof.

78. The method of claim 58, comprising replacing the inserted punctum plug with a second punctum plug having the same, lower or higher dosage of the agent following an interval of time.

81. The method of claim 78, wherein the step of replacing the punctum plug is repeated until the subject no longer requires treatment.

82. The method of claim 58, wherein the comforting agent is selected from the group consisting of polyvinyl alcohol (PVA), polyethylene oxide (PEO), polyvinyl pyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), carboxy methylcellulose (CMC), glycerin, simethicone, and sodium hyaluronate.

83. The method of claim 58, wherein the comforting agent is released for at least one week, at least two weeks, or at least one month.

64-67. -67. (canceled)

69-71. -71. (canceled)

73. (canceled)

75-77. -77. (canceled)

79-80. -80. (canceled)

84. (canceled)